Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
X-TOLE2: XEN1101 in Focal-Onset Seizures
NCT05614063Phase 3Completed
- Sponsor
- Xenon Pharmaceuticals
- Start
- Nov 2022
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of azetukalner in focal onset seizure, sponsored by Xenon Pharmaceuticals. Started Nov 2022; status: completed.
02
Drugs
azetukalner
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT05614063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05614063.